Tag Archives: NVAX

The Delta Variant Gives Novavax an Outside Chance of Upside

Originally, when the novel coronavirus first became a thing, Novavax (NASDAQ:NVAX) showed great promise. While other vaccine developers were experimenting with pioneering nucleic-acid-based technologies, Novavax went with a subunit mechanism, a proven approach used in the hepatitis B vaccine. Theoretically, that should have been great news for NVAX stock and it was, at least for a while.

Source: Ascannio/Shutterstock.com

No matter how you look at it, Novavax is a Covid-19 winner. Prior to the pandemic, the company was staring at a complete implosion, having failed to deliver....More>>>

What Are the Prospects for Moderna?

Moderna’s (NASDAQ:MRNA) revenue and profits are soaring. Its share price is up more than 280% so far this year. The company plans to build its messenger RNA (mRNA) pipeline. In this Motley Fool Live video recorded on Aug. 25, 2021, Motley Fool contributors Keith Speights and Brian Orelli address a viewer’s question about what the prospects are for Moderna going forward.

Keith Speights: John L. has a question, “What are the prospects for Moderna?” Ticker there, of course, is MRNA. Great ticker for that Moderna picked up there. John says, “I’ve been....More>>>

Why Moderna, BioNTech, and Novavax Stocks Sank Today

What happened

Shares of three leading COVID-19 vaccine makers sank on Thursday. As of the market close, BioNTech (NASDAQ:BNTX) stock was down 8.8%. Shares of Moderna (NASDAQ:MRNA) and Novavax (NASDAQ:NVAX) fell 5.8% and 4.2%, respectively.

None of the companies announced any developments. However, there were a couple of stories that were likely related to the vaccine stocks sinking.

CNBC reported that some scientists are criticizing the U.S. government’s decision to move forward with third booster doses of messenger RNA (mRNA) vaccines as premature. Also, results from....More>>>

Novavax Stock Is a Steal Here If You Believe It Will Come Through

Novavax (NASDAQ:NVAX) stock could trade in the $100 billion market capitalization range like BioNTech (NASDAQ:BNTX) or Moderna (NASDAQ:MRNA). Except, unlike those companies, Novavax has not yet delivered.

Source: Ascannio/Shutterstock.com

It might be among the most-watched firms that did not yet bring a Covid-19 vaccine to market.

Chances are low that it will slump like Altimmune (NASDAQ:ALT) after it discontinued its nasal Covid-19 vaccine.

By comparison, Inovio Pharmaceuticals (NASDAQ:INO) is on the mend after Brazil approved its vaccine candidate.

If....More>>>

The Delta Variant Gives Novavax an Outside Chance of Upside

Originally, when the novel coronavirus first became a thing, Novavax (NASDAQ:NVAX) showed great promise. While other vaccine developers were experimenting with pioneering nucleic-acid-based technologies, Novavax went with a subunit mechanism, a proven approach used in the hepatitis B vaccine. Theoretically, that should have been great news for NVAX stock and it was, at least for a while.

Source: Ascannio/Shutterstock.com

No matter how you look at it, Novavax is a Covid-19 winner. Prior to the pandemic, the company was staring at a complete implosion, having failed to deliver....More>>>